Aeglea BioTherapeutics, Inc. Purchase Agreements
9 Contracts & Agreements
- Securities Purchase Agreement, dated as of March 18, 2024, by and among Spyre Therapeutics, Inc. and each purchaser identified on Annex A thereto (Filed With SEC on March 18, 2024)
- Asset Purchase Agreement, dated July 27, 2023, by and between the Company and Immedica Pharma AB (Filed With SEC on December 22, 2023)
- Securities Purchase Agreement, dated December 7, 2023, by and among Spyre Therapeutics, Inc. and each purchaser identified on Annex A thereto (Filed With SEC on December 22, 2023)
- Securities Purchase Agreement, dated as of December 7, 2023, by and among Spyre Therapeutics, Inc. and each purchaser identified on Annex A thereto (Filed With SEC on December 8, 2023)
- Asset Purchase Agreement, dated July 27, 2023, by and between Aeglea BioTherapeutics, Inc. and Immedica Pharma AB (Filed With SEC on November 15, 2023)
- Securities Purchase Agreement, dated June 22, 2023, by and among the Registrant and the purchasers named therein (Filed With SEC on November 15, 2023)
- Asset Purchase Agreement, dated July 27, 2023, by and between Aeglea BioTherapeutics, Inc. and Immedica Pharma AB (Filed With SEC on August 11, 2023)
- Securities Purchase Agreement, dated as of June 22, 2023, by and among Aeglea BioTherapeutics, Inc. and each purchaser identified on Annex A thereto (Filed With SEC on June 23, 2023)
- Form of Securities Purchase Agreement, dated as of May 5, 2022, by and among Aeglea BioTherapeutics, Inc. and the purchasers identified therein (Filed With SEC on May 6, 2022)
